Cornea & External Disease · Surgeon Series
One nerve decides
whether shingles stays
on the skin, or reaches the eye.
Herpes zoster ophthalmicus happens when the virus behind chickenpox reactivates in the one nerve branch that supplies both the eye and the tip of the nose. A rash in a very specific place can predict it. A narrowing window for antivirals can change how it plays out. Here is the pathway, the sign, and the evidence.
with strongest evidence
that reaches the eye
shingles, any site
Section 01 — What HZO Actually Is
Chickenpox never
really leaves.
It waits in a nerve.
Almost everyone who has had chickenpox is carrying a dormant copy of varicella-zoster virus (VZV) in their nerve ganglia, sitting quietly since childhood. When it reactivates decades later, most people know it as shingles: a band of painful blisters on the torso or a limb, following one dermatome on one side of the body. Herpes zoster ophthalmicus (HZO) is the same reactivation happening in a specific place — the ophthalmic division (V1) of the trigeminal nerve, the branch that supplies the forehead, upper eyelid, the side of the nose, and the eye itself.
That single fact of geography is what makes HZO a distinct clinical problem rather than just "shingles near the face." The trigeminal ganglion sits near the ear, and its ophthalmic branch fans out to the skin of the brow and scalp, the cornea, the sclera, and deeper structures inside the eye. Reactivated virus travelling down that branch does not stay confined to skin — it can inflame every layer of the eye it passes on the way, which is why HZO carries a materially higher risk of vision-threatening complications than shingles occurring almost anywhere else on the body.
Herpes zoster ophthalmicus is shingles in the ophthalmic (V1) division of the trigeminal nerve — the branch that supplies the eye as well as the forehead and nose. It is commonly cited as accounting for roughly one in ten to one in five of all zoster cases, and its risk rises sharply with age and with immune suppression. Because the same nerve innervates the cornea, uvea, and even the retina's blood supply in rare cases, HZO can produce keratitis, uveitis, elevated eye pressure, and chronic pain long after the rash itself has healed. Antivirals started early change the course; a specific rash location — the tip of the nose — is the clinical clue that predicts which cases are more likely to involve the eye.
Section 02 — Interactive
The window that
narrows with every hour.
The single most actionable variable in HZO is time: how many hours have passed since the first vesicle appeared before an antiviral is started. Move the slider below to see how the treatment-benefit window is generally framed, and why the same nasociliary branch that reaches the eye also reaches the tip of the nose.
The nasociliary nerve branches early: one path runs to the skin at the tip and side of the nose, the other runs onward to the cornea and inside the eye. That shared origin is the entire reason a rash on the nose is clinically useful — it is not a coincidence of geography, it is the same nerve trunk reporting inflammation in two places at once. A positive Hutchinson's sign does not guarantee eye involvement, and its absence does not rule it out, but it reliably raises the index of suspicion enough that most guidelines treat it as a reason for prompt ophthalmic examination regardless of whether the eye feels symptomatic yet.
Section 03 — Reading the Rash
A rash that stops
exactly at the midline.
One of the more distinctive features of any shingles rash, including HZO, is that it respects the dermatome precisely — it does not cross the midline of the forehead or scalp, because the nerve supply on the other side belongs to a separate ganglion entirely. That sharp midline cutoff is itself a diagnostic clue, distinguishing HZO from other facial rashes that do not follow a single nerve's territory.
The rash typically evolves over one to two weeks: a prodrome of pain, tingling or burning in the affected area (sometimes for several days before any visible lesion), followed by erythema, then clusters of vesicles, which progress to pustules and finally crust over. Pain can range from mild to severe, and in a meaningful minority of patients precedes the rash by enough time that the initial presentation is mistaken for a headache, sinus problem, or dental issue until the skin lesions appear.
| Rash phase | What is happening | Why it matters for the eye |
|---|---|---|
| Prodrome (days before rash) | Pain, tingling, or burning along the V1 distribution, often without visible skin change yet | Easy to miss or misattribute; no ocular findings yet but virus is already active in the nerve |
| Erythema & vesicles (days 1–5) | Painful, grouped blisters appear strictly within the V1 dermatome, stopping at the midline | The antiviral window is measured from here; check for Hutchinson's sign at this stage |
| Pustules & crusting (days 5–14) | Vesicles cloud, then crust and begin to heal over one to two weeks | New ocular complications (keratitis, uveitis) can still emerge during or after this phase |
| Resolution (weeks to months) | Skin heals, sometimes with scarring; pain often subsides but can persist | Chronic or recurrent keratitis, uveitis and neuralgia can continue for months to years |
Section 04 — What It Can Do to the Eye
Almost every layer
the eye has, is on the table.
Because the trigeminal nerve's ophthalmic branch reaches essentially every structure at the front of the eye and, more rarely, structures at the back, HZO's ocular complications span a genuinely wide range of severity — from a mild, self-limited conjunctivitis to sight-threatening retinal disease.
| Structure | What can happen | Typical timing |
|---|---|---|
| Conjunctiva | Conjunctivitis — the most common ocular finding, usually mild | Acute phase |
| Episclera / sclera | Episcleritis or scleritis, sometimes with significant pain and redness | Acute to subacute |
| Cornea | Punctate epithelial keratitis early; later, coarse pseudodendrites (distinct from true herpes simplex dendrites), nummular keratitis, or deeper disciform stromal keratitis; chronic cases can develop neurotrophic keratopathy from corneal nerve damage | Acute through chronic — can recur for years |
| Uveal tract | Anterior uveitis, often with elevated intraocular pressure from trabeculitis; can become chronic or relapsing | Acute, frequently recurrent |
| Retina (rare) | Acute retinal necrosis — uncommon but vision-threatening, occasionally bilateral | Can occur weeks to months later, including in the fellow eye |
| Cranial nerves (rare) | Ocular motor nerve palsies causing double vision, usually self-resolving | Subacute |
| Sensory nerve | Postherpetic neuralgia — chronic pain in the affected dermatome persisting after the rash heals | Can persist for months to years, more likely and more severe with older age |
What makes HZO clinically demanding is not any single complication but the combination: an eye can be dealing with corneal surface disease, intraocular inflammation, and elevated pressure simultaneously, each requiring a different treatment emphasis, while the patient is also managing significant nerve pain from the same episode. This is also why HZO is not a condition that resolves neatly with the rash — recurrent or smouldering keratitis and uveitis, flaring intermittently without any new visible rash, is a recognised long-term pattern that can continue long after the acute episode most people think of as "having shingles" is over.
Section 05 — The Evidence on Treatment
What antivirals
demonstrably change.
Oral antivirals — acyclovir, valacyclovir, or famciclovir — are the backbone of acute HZO treatment, and the evidence for starting them early is old, consistent, and still the basis of current guidelines.
Illustrative visualisation of the direction and rough magnitude reported across the acute-treatment literature — see References for source studies. Not pooled meta-analytic effect sizes.
The foundational trial in this area, an oral acyclovir study in acute HZO published in Ophthalmology in the 1980s, established that early treatment reduced the incidence of dendriform keratitis, stromal keratitis, and uveitis compared with placebo, setting the template that valacyclovir and famciclovir — both better absorbed orally, allowing less frequent dosing — have since built on with broadly similar acute-phase outcomes. That early-treatment benefit is the single most consistent finding in the literature and the reason the 72-hour framing persists in current guidance.
What antivirals have not been shown to reliably do is eliminate postherpetic neuralgia once it is established, or fully prevent the chronic, relapsing ocular inflammation some patients experience for months or years afterward. That open question is exactly what the Zoster Eye Disease Study (ZEDS), a large NIH-funded multicentre randomised trial, was designed to address — testing whether a full year of low-dose suppressive valacyclovir, given after the standard acute course, reduces new or worsening HZO complications compared with placebo. Reported results have been more equivocal than many clinicians expected going in, which is worth checking against the published primary paper directly rather than assuming a settled answer either way.
treatment window
rash resolution
(V1) responsible
Section 06 — Risk, Honestly Stated
Neither treatment
nor prevention
is a guarantee.
A useful account of HZO does not oversell what antivirals or vaccination can do. Both genuinely reduce risk. Neither reduces it to zero, and both come with real limitations worth stating plainly.
| Intervention | Documented benefit | Limitation |
|---|---|---|
| Early oral antivirals | Reduces acute pain, new lesion formation, and acute ocular complication rates when started promptly | Benefit narrows the later treatment starts; does not reliably prevent postherpetic neuralgia once established |
| Prolonged suppressive antivirals | Studied specifically for recurrent or chronic HZO ocular inflammation (ZEDS) | Evidence for routine year-long use remains an active question, not a settled recommendation for every case |
| Recombinant zoster vaccine | Approximately 90% efficacy against shingles overall in pivotal trials, recommended for adults 50+ | Reduces but does not eliminate risk; does not treat an active episode |
| Topical steroids for keratitis/uveitis | Effective at controlling inflammation in corneal stromal disease and uveitis | Requires ophthalmologist supervision — inappropriate use can worsen infectious causes or raise eye pressure |
Section 07 — Where This Meets Cataract Surgery
An old HZO episode
can still shape
a surgical plan.
HZO is not typically anyone's first thought when they think about cataract surgery, but chronic or recurrent HZO-related uveitis is a recognised, if less common, path to earlier or more complex cataract formation — and a history of it changes how a surgeon approaches the case.
A patient in their late sixties presents for cataract evaluation. Vision has declined gradually, consistent with an age-appropriate cataract, but the eye also has patches of iris atrophy and a few small posterior synechiae — adhesions between the iris and the underlying lens — that do not fit a routine, uncomplicated cataract. On questioning, the patient recalls a painful shingles rash across the forehead and around one eye roughly eight years earlier, treated with antivirals at the time and thought to be fully resolved.
That history changes the surgical plan in specific, practical ways: confirming the eye has been quiet for a meaningful stretch before scheduling, more deliberate management of a pupil that may not dilate well because of iris damage, closer control of intraoperative and postoperative inflammation, and careful anterior chamber protection with a cohesive OVD through a small, controlled incision — the same viscoelastic principle covered in the cohesive vs dispersive OVD guide — followed by standard intracameral antibiotic prophylaxis at the close, the same practice discussed in the intracameral moxifloxacin guide. None of this makes the surgery categorically higher-risk in a way that should alarm the patient; it makes it a case that benefits from being recognised for what it is before the first incision, not discovered mid-procedure.
This is also why a full ocular and medical history matters more in ophthalmology than a quick glance might suggest: an old, seemingly resolved shingles episode from years earlier is exactly the kind of detail that can quietly explain an atypical iris or an eye that inflames more easily than expected, long after the rash itself is a distant memory. For the acute-phase uveitis picture itself, in whatever eye it appears, the mechanisms and management overlap substantially with the general uveitis workup covered in the Uveitis guide, and the keratitis patterns HZO produces sit within the broader keratitis picture covered in the Corneal Ulcer & Keratitis guide.
Section 08 — FAQ
Frequently asked questions
about herpes zoster ophthalmicus.
Herpes zoster ophthalmicus (HZO) is shingles involving the ophthalmic division (V1) of the trigeminal nerve — the branch that supplies the forehead, upper eyelid, nose and the eye itself. It happens when varicella-zoster virus, which stays dormant in nerve ganglia after a childhood chickenpox infection, reactivates decades later and travels down that specific nerve branch. It is commonly cited as accounting for roughly one in ten to one in five of all shingles cases.
Hutchinson's sign is a shingles rash on the tip, side or root of the nose. It matters because that skin is supplied by the external nasal branch of the nasociliary nerve, and the nasociliary nerve also supplies the cornea and the inside of the eye. A rash there means the same nerve branch serving the eye is inflamed, so many published case series report ocular involvement in roughly half or more of patients with a positive sign — though it is not perfectly predictive in either direction, and eye involvement can still occur without it.
Starting oral antivirals within 72 hours of the first vesicle appearing has the strongest evidence for reducing acute pain, limiting new lesion formation and lowering the risk of chronic complications. That window is a target, not a hard cutoff. Guidelines still generally recommend antiviral treatment for patients presenting later, particularly if new vesicles are still forming or there is any sign of eye involvement, since the drug can still limit ongoing viral replication even after the ideal window has passed.
HZO can affect nearly every structure of the eye: conjunctivitis is the most common finding, followed by episcleritis or scleritis, several forms of keratitis (including pseudodendrites, which differ from true herpes simplex dendrites), anterior uveitis often with elevated eye pressure, and — rarely — acute retinal necrosis or cranial nerve palsies. Postherpetic neuralgia, chronic nerve pain persisting after the rash heals, is also common and tends to be more severe with older age.
Recurrence is uncommon but documented, and chronic or relapsing keratitis and uveitis can flare intermittently for years after the acute rash has fully healed, even without a new visible rash. This relapsing pattern is part of why some clinicians consider longer courses of low-dose suppressive antiviral therapy in patients with recurrent ocular inflammation, an approach studied directly by the NIH-funded Zoster Eye Disease Study.
The recombinant zoster vaccine (marketed as Shingrix) is recommended by health authorities for adults aged 50 and older, and for younger immunocompromised adults, and was shown in its pivotal trials to be approximately 90 percent effective at preventing shingles overall. Because HZO is simply shingles occurring in a particular nerve branch, reducing overall shingles risk reduces HZO risk too, though the vaccine does not eliminate the possibility entirely.
Yes. Chronic or recurrent HZO-related uveitis can accelerate cataract formation, and eyes with a history of HZO often have iris atrophy, a poorly dilating pupil, or posterior synechiae from prior inflammation. Surgeons typically plan for a quieter eye first, sometimes with perioperative antiviral cover, more deliberate pupil and iris management, and careful anterior chamber protection and infection prophylaxis during the case itself.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Cornea & External Disease · Surgeon Series
One nerve decides
whether shingles stays
on the skin, or reaches the eye.
Herpes zoster ophthalmicus happens when the virus behind chickenpox reactivates in the one nerve branch that supplies both the eye and the tip of the nose. A rash in a very specific place can predict it. A narrowing window for antivirals can change how it plays out. Here is the pathway, the sign, and the evidence.
with strongest evidence
that reaches the eye
shingles, any site
Section 01 — What HZO Actually Is
Chickenpox never
really leaves.
It waits in a nerve.
Almost everyone who has had chickenpox is carrying a dormant copy of varicella-zoster virus (VZV) in their nerve ganglia, sitting quietly since childhood. When it reactivates decades later, most people know it as shingles: a band of painful blisters on the torso or a limb, following one dermatome on one side of the body. Herpes zoster ophthalmicus (HZO) is the same reactivation happening in a specific place — the ophthalmic division (V1) of the trigeminal nerve, the branch that supplies the forehead, upper eyelid, the side of the nose, and the eye itself.
That single fact of geography is what makes HZO a distinct clinical problem rather than just "shingles near the face." The trigeminal ganglion sits near the ear, and its ophthalmic branch fans out to the skin of the brow and scalp, the cornea, the sclera, and deeper structures inside the eye. Reactivated virus travelling down that branch does not stay confined to skin — it can inflame every layer of the eye it passes on the way, which is why HZO carries a materially higher risk of vision-threatening complications than shingles occurring almost anywhere else on the body.
Herpes zoster ophthalmicus is shingles in the ophthalmic (V1) division of the trigeminal nerve — the branch that supplies the eye as well as the forehead and nose. It is commonly cited as accounting for roughly one in ten to one in five of all zoster cases, and its risk rises sharply with age and with immune suppression. Because the same nerve innervates the cornea, uvea, and even the retina's blood supply in rare cases, HZO can produce keratitis, uveitis, elevated eye pressure, and chronic pain long after the rash itself has healed. Antivirals started early change the course; a specific rash location — the tip of the nose — is the clinical clue that predicts which cases are more likely to involve the eye.
Section 02 — Interactive
The window that
narrows with every hour.
The single most actionable variable in HZO is time: how many hours have passed since the first vesicle appeared before an antiviral is started. Move the slider below to see how the treatment-benefit window is generally framed, and why the same nasociliary branch that reaches the eye also reaches the tip of the nose.
The nasociliary nerve branches early: one path runs to the skin at the tip and side of the nose, the other runs onward to the cornea and inside the eye. That shared origin is the entire reason a rash on the nose is clinically useful — it is not a coincidence of geography, it is the same nerve trunk reporting inflammation in two places at once. A positive Hutchinson's sign does not guarantee eye involvement, and its absence does not rule it out, but it reliably raises the index of suspicion enough that most guidelines treat it as a reason for prompt ophthalmic examination regardless of whether the eye feels symptomatic yet.
Section 03 — Reading the Rash
A rash that stops
exactly at the midline.
One of the more distinctive features of any shingles rash, including HZO, is that it respects the dermatome precisely — it does not cross the midline of the forehead or scalp, because the nerve supply on the other side belongs to a separate ganglion entirely. That sharp midline cutoff is itself a diagnostic clue, distinguishing HZO from other facial rashes that do not follow a single nerve's territory.
The rash typically evolves over one to two weeks: a prodrome of pain, tingling or burning in the affected area (sometimes for several days before any visible lesion), followed by erythema, then clusters of vesicles, which progress to pustules and finally crust over. Pain can range from mild to severe, and in a meaningful minority of patients precedes the rash by enough time that the initial presentation is mistaken for a headache, sinus problem, or dental issue until the skin lesions appear.
| Rash phase | What is happening | Why it matters for the eye |
|---|---|---|
| Prodrome (days before rash) | Pain, tingling, or burning along the V1 distribution, often without visible skin change yet | Easy to miss or misattribute; no ocular findings yet but virus is already active in the nerve |
| Erythema & vesicles (days 1–5) | Painful, grouped blisters appear strictly within the V1 dermatome, stopping at the midline | The antiviral window is measured from here; check for Hutchinson's sign at this stage |
| Pustules & crusting (days 5–14) | Vesicles cloud, then crust and begin to heal over one to two weeks | New ocular complications (keratitis, uveitis) can still emerge during or after this phase |
| Resolution (weeks to months) | Skin heals, sometimes with scarring; pain often subsides but can persist | Chronic or recurrent keratitis, uveitis and neuralgia can continue for months to years |
Section 04 — What It Can Do to the Eye
Almost every layer
the eye has, is on the table.
Because the trigeminal nerve's ophthalmic branch reaches essentially every structure at the front of the eye and, more rarely, structures at the back, HZO's ocular complications span a genuinely wide range of severity — from a mild, self-limited conjunctivitis to sight-threatening retinal disease.
| Structure | What can happen | Typical timing |
|---|---|---|
| Conjunctiva | Conjunctivitis — the most common ocular finding, usually mild | Acute phase |
| Episclera / sclera | Episcleritis or scleritis, sometimes with significant pain and redness | Acute to subacute |
| Cornea | Punctate epithelial keratitis early; later, coarse pseudodendrites (distinct from true herpes simplex dendrites), nummular keratitis, or deeper disciform stromal keratitis; chronic cases can develop neurotrophic keratopathy from corneal nerve damage | Acute through chronic — can recur for years |
| Uveal tract | Anterior uveitis, often with elevated intraocular pressure from trabeculitis; can become chronic or relapsing | Acute, frequently recurrent |
| Retina (rare) | Acute retinal necrosis — uncommon but vision-threatening, occasionally bilateral | Can occur weeks to months later, including in the fellow eye |
| Cranial nerves (rare) | Ocular motor nerve palsies causing double vision, usually self-resolving | Subacute |
| Sensory nerve | Postherpetic neuralgia — chronic pain in the affected dermatome persisting after the rash heals | Can persist for months to years, more likely and more severe with older age |
What makes HZO clinically demanding is not any single complication but the combination: an eye can be dealing with corneal surface disease, intraocular inflammation, and elevated pressure simultaneously, each requiring a different treatment emphasis, while the patient is also managing significant nerve pain from the same episode. This is also why HZO is not a condition that resolves neatly with the rash — recurrent or smouldering keratitis and uveitis, flaring intermittently without any new visible rash, is a recognised long-term pattern that can continue long after the acute episode most people think of as "having shingles" is over.
Section 05 — The Evidence on Treatment
What antivirals
demonstrably change.
Oral antivirals — acyclovir, valacyclovir, or famciclovir — are the backbone of acute HZO treatment, and the evidence for starting them early is old, consistent, and still the basis of current guidelines.
Illustrative visualisation of the direction and rough magnitude reported across the acute-treatment literature — see References for source studies. Not pooled meta-analytic effect sizes.
The foundational trial in this area, an oral acyclovir study in acute HZO published in Ophthalmology in the 1980s, established that early treatment reduced the incidence of dendriform keratitis, stromal keratitis, and uveitis compared with placebo, setting the template that valacyclovir and famciclovir — both better absorbed orally, allowing less frequent dosing — have since built on with broadly similar acute-phase outcomes. That early-treatment benefit is the single most consistent finding in the literature and the reason the 72-hour framing persists in current guidance.
What antivirals have not been shown to reliably do is eliminate postherpetic neuralgia once it is established, or fully prevent the chronic, relapsing ocular inflammation some patients experience for months or years afterward. That open question is exactly what the Zoster Eye Disease Study (ZEDS), a large NIH-funded multicentre randomised trial, was designed to address — testing whether a full year of low-dose suppressive valacyclovir, given after the standard acute course, reduces new or worsening HZO complications compared with placebo. Reported results have been more equivocal than many clinicians expected going in, which is worth checking against the published primary paper directly rather than assuming a settled answer either way.
treatment window
rash resolution
(V1) responsible
Section 06 — Risk, Honestly Stated
Neither treatment
nor prevention
is a guarantee.
A useful account of HZO does not oversell what antivirals or vaccination can do. Both genuinely reduce risk. Neither reduces it to zero, and both come with real limitations worth stating plainly.
| Intervention | Documented benefit | Limitation |
|---|---|---|
| Early oral antivirals | Reduces acute pain, new lesion formation, and acute ocular complication rates when started promptly | Benefit narrows the later treatment starts; does not reliably prevent postherpetic neuralgia once established |
| Prolonged suppressive antivirals | Studied specifically for recurrent or chronic HZO ocular inflammation (ZEDS) | Evidence for routine year-long use remains an active question, not a settled recommendation for every case |
| Recombinant zoster vaccine | Approximately 90% efficacy against shingles overall in pivotal trials, recommended for adults 50+ | Reduces but does not eliminate risk; does not treat an active episode |
| Topical steroids for keratitis/uveitis | Effective at controlling inflammation in corneal stromal disease and uveitis | Requires ophthalmologist supervision — inappropriate use can worsen infectious causes or raise eye pressure |
Section 07 — Where This Meets Cataract Surgery
An old HZO episode
can still shape
a surgical plan.
HZO is not typically anyone's first thought when they think about cataract surgery, but chronic or recurrent HZO-related uveitis is a recognised, if less common, path to earlier or more complex cataract formation — and a history of it changes how a surgeon approaches the case.
A patient in their late sixties presents for cataract evaluation. Vision has declined gradually, consistent with an age-appropriate cataract, but the eye also has patches of iris atrophy and a few small posterior synechiae — adhesions between the iris and the underlying lens — that do not fit a routine, uncomplicated cataract. On questioning, the patient recalls a painful shingles rash across the forehead and around one eye roughly eight years earlier, treated with antivirals at the time and thought to be fully resolved.
That history changes the surgical plan in specific, practical ways: confirming the eye has been quiet for a meaningful stretch before scheduling, more deliberate management of a pupil that may not dilate well because of iris damage, closer control of intraoperative and postoperative inflammation, and careful anterior chamber protection with a cohesive OVD through a small, controlled incision — the same viscoelastic principle covered in the cohesive vs dispersive OVD guide — followed by standard intracameral antibiotic prophylaxis at the close, the same practice discussed in the intracameral moxifloxacin guide. None of this makes the surgery categorically higher-risk in a way that should alarm the patient; it makes it a case that benefits from being recognised for what it is before the first incision, not discovered mid-procedure.
This is also why a full ocular and medical history matters more in ophthalmology than a quick glance might suggest: an old, seemingly resolved shingles episode from years earlier is exactly the kind of detail that can quietly explain an atypical iris or an eye that inflames more easily than expected, long after the rash itself is a distant memory. For the acute-phase uveitis picture itself, in whatever eye it appears, the mechanisms and management overlap substantially with the general uveitis workup covered in the Uveitis guide, and the keratitis patterns HZO produces sit within the broader keratitis picture covered in the Corneal Ulcer & Keratitis guide.
Section 08 — FAQ
Frequently asked questions
about herpes zoster ophthalmicus.
Herpes zoster ophthalmicus (HZO) is shingles involving the ophthalmic division (V1) of the trigeminal nerve — the branch that supplies the forehead, upper eyelid, nose and the eye itself. It happens when varicella-zoster virus, which stays dormant in nerve ganglia after a childhood chickenpox infection, reactivates decades later and travels down that specific nerve branch. It is commonly cited as accounting for roughly one in ten to one in five of all shingles cases.
Hutchinson's sign is a shingles rash on the tip, side or root of the nose. It matters because that skin is supplied by the external nasal branch of the nasociliary nerve, and the nasociliary nerve also supplies the cornea and the inside of the eye. A rash there means the same nerve branch serving the eye is inflamed, so many published case series report ocular involvement in roughly half or more of patients with a positive sign — though it is not perfectly predictive in either direction, and eye involvement can still occur without it.
Starting oral antivirals within 72 hours of the first vesicle appearing has the strongest evidence for reducing acute pain, limiting new lesion formation and lowering the risk of chronic complications. That window is a target, not a hard cutoff. Guidelines still generally recommend antiviral treatment for patients presenting later, particularly if new vesicles are still forming or there is any sign of eye involvement, since the drug can still limit ongoing viral replication even after the ideal window has passed.
HZO can affect nearly every structure of the eye: conjunctivitis is the most common finding, followed by episcleritis or scleritis, several forms of keratitis (including pseudodendrites, which differ from true herpes simplex dendrites), anterior uveitis often with elevated eye pressure, and — rarely — acute retinal necrosis or cranial nerve palsies. Postherpetic neuralgia, chronic nerve pain persisting after the rash heals, is also common and tends to be more severe with older age.
Recurrence is uncommon but documented, and chronic or relapsing keratitis and uveitis can flare intermittently for years after the acute rash has fully healed, even without a new visible rash. This relapsing pattern is part of why some clinicians consider longer courses of low-dose suppressive antiviral therapy in patients with recurrent ocular inflammation, an approach studied directly by the NIH-funded Zoster Eye Disease Study.
The recombinant zoster vaccine (marketed as Shingrix) is recommended by health authorities for adults aged 50 and older, and for younger immunocompromised adults, and was shown in its pivotal trials to be approximately 90 percent effective at preventing shingles overall. Because HZO is simply shingles occurring in a particular nerve branch, reducing overall shingles risk reduces HZO risk too, though the vaccine does not eliminate the possibility entirely.
Yes. Chronic or recurrent HZO-related uveitis can accelerate cataract formation, and eyes with a history of HZO often have iris atrophy, a poorly dilating pupil, or posterior synechiae from prior inflammation. Surgeons typically plan for a quieter eye first, sometimes with perioperative antiviral cover, more deliberate pupil and iris management, and careful anterior chamber protection and infection prophylaxis during the case itself.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Start writing here...
Herpes Zoster Ophthalmicus: Shingles in the Eye, Hutchinson's Sign & the Antiviral Window (2026 Guide)